ADMA Biologics (ADMA) Q3 2026 Earnings Call Transcript

ADMA Biologics reported Q3 2026 revenue of $141.1 million, up 5% year over year, while ASCENIV revenue rose 31% to $124.7 million and gross margin expanded 1,450 bps to 71%. Management reiterated full-year revenue guidance of at least $530 million and raised minimum adjusted EBITDA guidance to $275 million from $265 million and adjusted net income guidance to $180 million from $170 million. BIVIGAM revenue fell to $15.4 million from $19.4 million in Q2 amid pricing and channel pressures, and DSO was 110 days versus a 90–105-day target; the company also reported $181.4 million in year-to-date repurchases and constructive FDA feedback on investigational SG-001.

Analysis

The key earnings signal is mix, not broad-based demand: ADMA’s higher-margin ASCENIV is carrying both growth and operating leverage while BIVIGAM absorbs price competition. That makes reported profitability more sensitive to ASCENIV’s continued patient additions than the headline earnings growth suggests. A flat revenue floor alongside higher earnings floors also leaves execution dependent on mix and manufacturing yields; it is not evidence that the standard-IG pricing environment has turned.

Near term, favorable ASCENIV pull-through and raised earnings guidance support sentiment. Over 1–3 months, verify that patient utilization—not distributor ordering—supports growth, and that DSO falls toward target without relying on looser terms or channel loading. The real-world outcomes presentation may help physician adoption, but company-described findings in 127 patients are not yet proof of payer-driven uptake. BIVIGAM’s stabilization is an early indicator, not a recovery; management’s refusal to match rebates protects price discipline but can concede share.

Over 6–18 months, SG-001 adds option value, not a near-term valuation anchor: the proposed assay still requires validation, and an IND/timing and clinical execution remain unresolved. Q4 development spend is a cash cost before any commercial payoff. Repurchases support per-share results, but investors should assess them against the return on pipeline investment and cash conversion, especially with elevated receivables. GRFS and other plasma-derived IG suppliers are relevant competitive context; the call does not establish that their economics or market exposure match ADMA’s.

Contrarian read: market enthusiasm could over-credit buybacks and margin expansion as durable while underweighting product concentration, channel timing, and BIVIGAM’s pricing headwind. Without valuation and consensus data, avoid a price target or aggressive chase.

Key Decisions for Investors

• ADMA: Prefer a staged long on post-earnings pullbacks rather than chasing the initial reaction; the thesis is ASCENIV utilization plus mix-led earnings. Reassess if subsequent results show weakening end-user demand, a guidance reduction, or margin contraction.
• Track quarterly ASCENIV patient/prescriber trends, distributor pull-through versus orders, DSO, and BIVIGAM utilization/price. A failure to bring DSO back toward the stated range alongside continued receivables growth would weaken cash-quality confidence.
• Treat SG-001 as unpriced optionality until ADMA provides an IND timeline, assay validation progress, and trial details; do not underwrite the stated potential revenue opportunity as a base-case forecast.
• No MCK or GRFS trade is indicated by this call alone: distributor payment terms do not establish material incremental economics for MCK, and competitive references do not quantify a GRFS-specific gain or loss.